Search PubMed⌕ Search

Biomedical subjects

E Haupt

Publications and source records attributed to E Haupt.

At least 37 records · Page 2Linked to original sources
PubMed1989

Effect of the laser ridge on posterior capsule opacification.

The most common complication of extracapsular cataract extraction is posterior capsule opacification, which appears to result from the proliferation of anterior lens epithelium onto the posterior capsule. The presence of a posterior chamber intraocular lens has been shown to decrease the incidence of posterior capsule opacification, possibly by a barrier mechanism. This retrospective clinical study compares the effect of two different lens designs (with and without a laser ridge) on posterior capsule opacification requiring Nd:YAG laser posterior capsulotomy. Twenty-one of 101 patients (20.8%) with nonridged lenses required Nd:YAG laser posterior capsulotomies versus 13 of 86 patients (15.1%) with ridged lenses. Although these data showed a clinical benefit from using a ridged lens, no statistical difference in the incidence of posterior capsulotomy was noted. Further evaluation of capsular-optic surface apposition is needed.

Adolescent↗
PubMed1989

[Mitoguazone (methylglyoxal bis(guanylhydrazone))--its status and prospects].

Because of its severe side effects, initial clinical trials of the antineoplastic compound mitoguazone (Methyl-GAG, M-G) were ceased in the middle of 1960s. One decade later pharmacokinetically guided dose schedules as well as new experimental data on the antiproliferative mechanism of action stimulated new clinical studies. First results indicated that M-G had single-agent activity against various tumors such as acute leukemia and malignant lymphoma connected with acceptable tolerance. M-G seems to be effective especially in combination with other antineoplastic drugs. Its final evaluation may be reserved to further randomized trials. Recently, the psoriasis vulgaris is expected to be an additional field of the application of M-G. In this minireview data on synthesis, preclinical pharmacology, pharmacokinetics, biochemical effects and toxicology of M-G are given. Furthermore, clinical findings on M-G concerning its pharmacokinetic behaviour, antitumor and antipsoriatic activities are described.

Animals↗
PubMed1989

Relationship between age at time of cataract extraction and time interval before capsulotomy for opacification.

This retrospective study reviews the time interval between extracapsular cataract extraction with posterior chamber intraocular lens placement and neodymium (Nd):YAG laser posterior capsulotomy relative to the age of the patient at the time of cataract surgery. Two hundred thirteen consecutive laser procedures involving eyes that had had extracapsular cataract extraction within 6 years were reviewed. We found that there was an upper limit on the time interval from extracapsular cataract extraction to Nd:YAG posterior capsulotomy for all patients eventually requiring a Nd:YAG capsulotomy. This time limit appeared to be directly proportional to the age of the patient at the time of his or her cataract surgery: the older the patient at the time of surgery, the longer the period the patient was at risk for requiring a capsulotomy. Beyond this time limit, the likelihood that an Nd:YAG capsulotomy would be required was less than 2.5%. The prolonged period of risk for elderly patients may be related to an age-related decline in lenticular hyperplasia.

Adult↗
PubMed1987

[Treatment of type II diabetes using homologous intermediate-acting insulin combinations. Comparison of the effectiveness of 5 commonly used preparations].

Although intraindividual comparisons of commonly used human standard combination insulins have not been made, pharmacodynamic differences between preparations in the by now no vast insulin market have been highlighted. The action of five bio- or semisynthetic human insulins of all four manufacturers using the same galenic formula and with a fixed normal insulin content of 20-30% was tested at equal dosages in type IIa and type IIb diabetics with differing residual pancreatic secretion. No differences were demonstrated in onset, maximum or duration of action. The blood-sugar lowering effect of the preparations is particularly marked in the late morning hours and may, if not counteracted by adequate carbohydrate intake, lead to hypoglycaemia. Duration of action of the preparations depends on the individual extent of endogenous pancreatic insulin reserves.

Clinical Trials as Topic↗
PubMed1985

Impaired in vitro growth of PHA induced T lymphocyte colonies in hemodialyzed renal failure patients.

Using an in vitro method that allows the study of the colony forming capacity of phytohemagglutinin stimulated peripheral blood T lymphocytes, we have detected an impaired T cell colony formation in hemodialyzed renal failure patients. By contrast a near normal pattern of responses was observed in patients treated with a conservative therapy. The poor in vitro T cell responsiveness of hemodialyzed patients was not corrected by supplementing the cultures with an adherent cell contitioned medium prepared from normal donors. We conclude that an intrinsic defect of the T cell colony forming capacity exists in hemodialyzed patients.

Adult↗
PubMed1984

[Pharmacodynamics and pharmacokinetics of 2 glibenclamide preparations in type 2 diabetes. Intraindividual double-blind comparison of Euglucon 5 (HB 419) and Euglucon N (HB 420)].

A new galenic form of glibenclamide (with a higher specific surface area for better absorption) was compared with the conventional form in 12 insulin-dependent and glibenclamide-treated diabetics (three women, nine men; aged 37-60 years) in a double-blind controlled crossover study. There was more rapid absorption, with a maximal serum concentration after 1 1/2 hours, compared with the usual preparation which gave a lower longer-sustained maximum of serum-glibenclamide level between 1 1/2 and 4 hours. In addition, there was more complete absorption so that the needed daily dose was decreased: 3.5 mg of the new form was bio-equivalent to 5 mg of the ordinary form. Duration of effect of the new form was not shorter despite different pharmacokinetics. Response of serum insulin and C-peptide level was the same in the two forms. On the other hand, the blood-glucose profile was significantly better with the new form.

Adult↗
PubMed1981

[Oral glucose tolerance tests--with or without estimation of serum insulin? (author's transl)].

Blood glucose and serum insulin values were determined after oral glucose tolerance tests in 528 persons with suspected pathological or disturbed glucose tolerance. Results were evaluated depending on sex, age, overweight, and familial diabetes. There were no differences of serum insulin secretion and behaviour of blood sugar between males and females. With increasing age there was a marked decrease of insulin secretion. In contrast there was increased hyperinsulinaemia with increasing overweight. This was particularly evident in persons with comparably reduced glucose tolerance but with different body weight. "Classical" changes of insulin secretion, as described for prediabetes and manifest diabetes in contrast to persons with normal metabolism, were only seen in selected groups of probands with normal weight. Serum insulin shows greater variability than blood glucose. Estimations of insulin are not necessary when assessing disturbances of glucose tolerance.

Administration, Oral↗
PubMed1981

Erythrocytosis associated with a dermoid cyst of the ovary and erythropoietic activity of the tumour fluid.

A patient with dermoid cyst of the ovary and erythrocytosis is described. Surgical removal of the tumour was followed by a progressive decrease of the red cell mass with remission of the haematological abnormalities. Tumor fluid contained significant erythropoietic stimulating activity. This seems to be the first documented case of erythrocytosis associated with ovarian cyst.

Aged↗
PubMed1979

Multiple myeloma without detectable Ig synthesis.

A case of nonproductor myeloma is reported. The diagnosis was supported by the radiological findings, the heavy marrow infiltration of malignant plasma cells, the absence of a monoclonal component in the serum or urine and the failure to demonstrate intracytoplasmic immunoglobulins with immunoifluorescent techniques. The clinical findings of our patient are similar to those reported for the 5 cases of nonproductor myeloma described so far, indicating that there are no characteristic features differentiating nonproductor myeloma from productor myelomas.

Bone Marrow↗
PubMed1977

[Secondary failures in modern therapy of diabetes mellitus with blood glucose lowering sulfonamides (author's transl)].

The analysis of the case histories of 914 diabetics exclusively treated with blood glucose lowering sulfonamides in a university clinic outpatient station yielded an annual secondary failure rate of 5-10 p.c. Cumulative incidence calculations showed a continuous increase of secondary failure depending on the duration of treatment. Thus less than 20 p.c. of the diabetics have a chance of a satisfactory long-term therapy after 10 years of treatment. Any dependency of secondary failure from age at onset of diabetes could not be proved. Both "old" and "new" sulfonamide derivatives were equally subject to secondary failure. Changing the treatment from a therapy using grammscale derivatives to any of the modern milligramm-scale substances has been more or less equally "successfull" but lastly unsatisfactory. Diabetics with secondary failure show more overweight than patients with positive long-term treatment

Blood Glucose↗